The body of evidence supporting measurable residual disease (MRD) assessment in routine patient care is growing. Leading experts share their views on MRD, the evolving role of MRD testing in lymphoid cancers, and insights on incorporating clonoSEQ (Adaptive Biotechnologies) into clinical practice decisions to assess MRD.
Read article.
Posted on 5/14/2021
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
